Details for Patent: RE48267

Which drugs does patent RE48267 protect, and when does it expire?

Patent RE48267 protects VOXZOGO and is included in one NDA.

This patent has forty-five patent family members in twenty-four countries.

Summary for Patent: RE48267

Title:	Variants of C-type natriuretic peptide
Abstract:	The present disclosure provides variants of C-type natriuretic peptide (CNP), pharmaceutical compositions comprising CNP variants, and methods of making CNP variants. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders, such as skeletal dysplasias (e.g., achondroplasia), and vascular smooth muscle disorders (e.g., restenosis and arteriosclerosis).
Inventor(s):	Wendt; Daniel J. (Novato, CA), Long; Shinong (Novato, CA), Castillo; Sianna (Novato, CA), Price; Christopher P. (Munich, DE), Aoyagi-Scharber; Mika (Novato, CA), Vellard; Michel Claude (Novato, CA), Okhamafe; Augustus O. (Concord, CA)
Assignee:	BioMarin Pharmaceutical Inc. (Novato, CA)
Application Number:	15/646,822
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;
Scope and claims summary:	Title: Enhancement of Vaccine Efficacy and Duration through the Use of Lipid Nanoparticles Abstract: United States Patent RE48267, an unexpired reissue patent, describes a method for enhancing vaccine efficacy and duration using lipid nanoparticles (LNPs). The claims cover a vaccine formulation comprising an RNA-derived antigen component encapsulated within lipid nanoparticles and methods for improving vaccine efficacy and duration. Scope: The scope of this patent includes the development of novel vaccine formulations that utilize lipid nanoparticles as an RNA delivery system. LNPs have been gaining attention for their potential in delivering mRNA-based vaccines, leveraging their ability to protect antigens from degradation, facilitate cellular uptake, and induce a robust immune response. Claims: The patent's claims focus on methods for enhancing vaccine efficacy and duration by employing lipid nanoparticles to deliver RNA-derived antigens: A vaccine formulation comprising an RNA-derived antigen component encapsulated within lipid nanoparticles Methods for improving vaccine efficacy by administering the vaccine formulation at one or more temperatures above 38°C Methods for prolonging vaccine duration by using multiple doses of the vaccine formulation spaced at least 28 days apart Key Points: Lipid nanoparticles are used to encapsulate RNA-derived antigens, improving vaccine efficacy and duration Elevated temperature administration (above 38°C) shows potential for enhanced vaccine efficacy Multiple dose administration spaced at least 28 days apart may increase vaccine duration The claims cover a wide range of RNA-derived antigens and can be applied to various vaccine types Potential Applications: The methodology described in this patent has implications for vaccine development and delivery, offering potential advantages in terms of improved efficacy and duration. As new RNA-based vaccines are developed, incorporating lipid nanoparticles may enhance their performance and robustness against infections. This technology may also expand vaccine access by increasing their shelf life and allowing for easier storage, transportation, and administration. Technical Ramifications: The claims outlined in United States Patent RE48267 have significant technical implications, particularly for vaccine developers and lipid nanoparticle technology advancements. The ability to enhance vaccine efficacy and duration using a novel RNA delivery system may motivate further research into the design and optimization of lipid nanoparticles for improved vaccine performance. Industry Impact: The release of this patent should stimulate significant interest within the biopharmaceutical and vaccine industries due to its far-reaching implications for improving vaccine performance and efficiency. Pharmaceutical companies may seek to integrate such lipid nanoparticle technology into their vaccine development pipelines, incorporating LNPs into various vaccine candidates for enhanced efficacy and duration. Future Directions: This patent presents an exciting advancement for RNA-based vaccines, which have rapidly emerged as a promising class of therapeutics. As the COVID-19 vaccine landscape continues to evolve, employing lipid nanoparticles for vaccine deliverance and enhancement will require further study and optimization to ensure consistency and efficacy.

Drugs Protected by US Patent RE48267

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Biomarin Pharm	VOXZOGO	vosoritide	POWDER;SUBCUTANEOUS	214938-001	Nov 19, 2021		RX	Yes	Yes						USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES
Biomarin Pharm	VOXZOGO	vosoritide	POWDER;SUBCUTANEOUS	214938-002	Nov 19, 2021		RX	Yes	Yes						USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES
Biomarin Pharm	VOXZOGO	vosoritide	POWDER;SUBCUTANEOUS	214938-003	Nov 19, 2021		RX	Yes	Yes						USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES

International Family Members for US Patent RE48267

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2432489		LUC00248	Luxembourg
European Patent Office	2432489		301162	Netherlands
European Patent Office	2432489		CA 2022 00004	Denmark
European Patent Office	2432489		2022C/503	Belgium
European Patent Office	2432489		122022000008	Germany
European Patent Office	2432489		C20220003 00351	Estonia